Fierce Biotech news story
After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the affected trials.
After discussions with the FDA, Gilead has “discontinued safety follow-up” for the phase 2/3 Wonders-2 trial, “effectively terminating the study,” a company spokesperson confirmed to Fierce Biotech.
Wonders-2 and its sibling phase 2/3 study Wonders-1, also paused, were testing GS-1720, an integrase strand transfer inhibitor, and GS-4182, a capsid inhibitor, against Gilead’s approved HIV med Biktarvy.
Read the full news story here.
Source : Fierce Biotech
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.